Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome

Blood

Volumn 95, Issue 4, 2000, Pages 1175-1179

  Thompson, John A ^a   Gilliland, D Gary ^b   Prchal, Josef T ^b   Bennett, John M ^b   Larholt, Kay ^b   Nelson, Richard A ^b   Rose, Esther H ^b   Dugan, Margaret H ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATOMEGALY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MALE; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; SKIN MANIFESTATION; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 0034651839     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1175.004k51_1175_1179     Document Type: Article

References (16)

1. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1988;82:705.
2. Cheson BD. The myelodysplastic syndromes: current approaches to therapy. Ann Int Med. 1990;112:932.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079.
4. Vadhan-Raj S, Hittelman WN, Lepe-Zuniga JL, Gutterman JU, Broxmeyer HE. Regulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes. Blood. 1990;75:1749.
5. Markham A, Bryson HM. Epoetin alfa: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs. 1995;49:232.
6. Verhoef GEG, Zachee P, Ferrant A, et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol. 1992;64:16.
7. Stenke L, Wallvik J, Celsing F, Hast R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol. 1993;84:232.
8. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 1995;89:831.
9. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344.
10. Migliaccio G, Migliaccio AR, Adamson JW. In vitro differentiation of human granulocyte macrophage and erythroid progenitors: comparative analysis of the influence of recombinant human erythropoietin, G-CSF, GM-CSF and IL-3 in serum-supplemented and serum-deprived cultures. Blood. 1988;72:248.
11. Hansen PB, Johnsen HE, Hippe E, Hellström-Lindberg E, Ralfkiaer E. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Hematol. 1993;44: 229.
12. Pene R, Appelbaum FR, Fisher L, et al. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous bone marrow transplantation. Bone Marrow Transplant. 1993;11:219.
13. World Health Organization. WHO Handbook for Reporting Results of Cancer Results. Geneva: 1979.
14. Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics and hematological effects. J Clin Oncol. 1989;7:629.
15. Vadhan-Raj S, Kaating M, LeMaistre A, et al. Effects of recombinant human granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987; 317:1545.
16. Herrmann F, Mertelsmann R, Lindemann A, et al. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome. Biotech Ther. 1991;2:299.